In a transformative study published in the journal Science Translational Medicine, an international team of researchers has made a significant breakthrough in the understanding and potential treatment of multiple sclerosis ...
Apr 4, 2024
0
115
Treatment-resistant depression (TRD) is a particularly challenging form of major depressive disorder. As Albino Oliveira-Maia, head of the Champalimaud Foundation's Neuropsychiatry Unit and the study's national coordinator ...
Oct 4, 2023
0
77
Clonal hematopoiesis is a biological process in which a blood stem cell (the population that gives rise to a variety of blood cell types) acquires an advantageous mutation and outgrows neighboring cells. Clonal hematopoiesis ...
Aug 2, 2022
0
23
Post-traumatic stress disorder (PTSD) affects millions of people each year, mostly survivors and witnesses of terrifying or shocking events, such as warfare, assaults or disasters. Because existing treatments don't work for ...
Mar 22, 2022
1
530
A large analysis of health records from 87 health care centers across the United States found that people taking a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, ...
Nov 15, 2021
0
382
Levels of dopamine and the placebo effect can determine whether patients with social anxieties improve when treated with SSRIs. A new study shows the effect was four times higher for patients with high expectations of the ...
Nov 8, 2021
0
158
A new type of magnetic brain stimulation brought rapid remission to almost 80% of participants with severe depression in a study conducted at the Stanford University School of Medicine.
Nov 1, 2021
0
212
A three-factor, composite clinical severity staging system can optimize treatment selection for the management of Meniere disease, according to a study published online Aug. 25 in Otolaryngology—Head and Neck Surgery.
Sep 6, 2023
0
1
A collaborative group led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) and the Division of Clinical Pathology & Molecular Pathology, Hong ...
Jul 4, 2023
0
3
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology.
Jun 14, 2023
0
2
